

5 October 2022  
ASX Code: MXC  
LSE Code: MXC

## Results of Shareholder's General Meeting

A  
S  
X  
  
R  
E  
L  
E  
A  
S  
E

**MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company')** would like to announce the results from the Company's General Meeting of shareholders held today, Wednesday, 5 October 2022, in accordance with ASX Listing Rule 3.13.2.

The Company confirms that all motions put to the meeting were voted by poll, with all resolutions carried by a clear majority.

Details of the proxy voting and voting outcomes for all motions put to the meeting are set out in the attached report.

--Ends--

**Authorised for release by the Company Secretary, for further information please contact:**

**MGC Pharmaceuticals Ltd**

Roby Zomer  
CEO & Managing Director  
+61 8 6382 3390  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

**UK Financial and Corporate Advisor**

**Hannam & Partners**  
Rupert Fane / Nilesh Patel  
+44 7810 056 104  
[rf@hannam.partners](mailto:rf@hannam.partners) / [nilesh@hannam.partners](mailto:nilesh@hannam.partners)

**UK PR Advisors**

**Tavistock**  
Charles Vivian / Tim Pearson  
+44 207 920 3150  
[mgcpharma@tavistock.co.uk](mailto:mgcpharma@tavistock.co.uk)

**MGC Pharmaceuticals Ltd**

David Lim  
Company Secretary  
+61 8 6382 3390  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

**UK Broker**

**Turner Pope**  
Andy Thacker  
+44 203 657 0050  
[info@turnerpope.com](mailto:info@turnerpope.com)

### About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels    

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Approval to issue Convertible Notes	Ordinary	423,593,890 89.74%	45,003,730 9.53%	3,456,204 0.73%	2,497,806	428,050,094 90.49%	45,003,730 9.51%	2,497,806	Carried
2 Ratification of prior issue of Convertible Notes	Ordinary	424,024,310 89.81%	44,621,631 9.45%	3,478,204 0.74%	2,427,485	428,502,514 90.57%	44,621,631 9.43%	2,427,485	Carried
3 Ratification of prior issue of Shares - Mercer Street Global Opportunity Fund, LLC	Ordinary	424,513,981 89.89%	44,234,505 9.37%	3,500,204 0.74%	2,299,940	429,014,185 90.65%	44,234,505 9.35%	2,299,940	Carried
4 Ratify prior issue of Shares Employees/Consultant	Ordinary	408,579,171 89.35%	45,247,768 9.89%	3,456,204 0.76%	108,502,487	413,035,375 90.13%	45,247,768 9.87%	108,502,487	Carried
5 Ratification of prior issue of Shares Bioheka Ltd	Ordinary	408,903,002 86.07%	62,576,307 13.17%	3,582,004 0.76%	90,724,317	413,485,006 86.86%	62,576,307 13.14%	90,724,317	Carried

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.